Abstract:Mesothelin (MSLN) is considered as a potential serological tumor biomarker for early diagnosis of pancreatic cancer. Nevertheless, low sensibility, high reagent consumption, and time costs of traditional detection methods limit their utility in clinical disease diagnoses. Here, we combined the immunoassay technique with microfluidic chips to develop a microfluidic immunoassay system (MIAS) that can be used for rapid semi-quantitative detection of serum MSLN levels. The MIAS was composed of 12 uniform structures, including 12 inlets, 12 reaction chambers, and one outlet allowing measurement of four samples with three repeats, simultaneously. A unique microarray cylinder was located at the end of each reaction chamber where immunoassay was performed to trap microspheres. A feasible interception efficiency (∼80%) was attained, with microspheres filling the reaction column. It has been demonstrated that fluorescence intensity is proportional to the MSLN concentration on the MIAS (R2 = 0.95). Subsequently, 16 clinical serum samples collected from Changhai Hospital, Shanghai were selected from eight patients with pancreatic cancers, four with pancreatitis, and four with other digestive system diseases (2 gastric cancer, 1 bile duct stricture, and 1 bile duct stones). MSLN levels for these samples were detected via MIAS. The results showed a significant correlation between MIAS and traditional enzyme-linked immunosorbent assay (ELISA), with the correlation coefficient, 0.93. The detection limit of MSLN fluorescence intensity and concentration was ∼6 a.u. and ∼20 pg/mL, respectively. The entire duration of analysis by MIAS decreased to ∼40 min compared to 2 h by ELISA. Statistical analysis of MIAS data revealed that MSLN was overexpressed in pancreatic cancer than in the others (P value = 0.0014). Moreover, the diagnostic accuracies of MSLN detected by MIAS and CA19-9 detected by ELISA in hospitals were 87.5 and 81.3%, respectively. MSLN is helpful for the early diagnosis of pancreatic cancer and other diseases, and it had a significant ability to discriminate between pancreatic and nonpancreatic cancers (P value = 0.0159). The results from this study show that MIAS has the potential to become a new serological tumor marker detection platform for rapid detection and semi-quantitative determination of MSLN and would have broad applications in early clinical diagnosis.

On‐Site Melanoma Diagnosis Utilizing a Swellable Microneedle‐Assisted Skin Interstitial Fluid Sampling and a Microfluidic Particle Dam for Visual Quantification of S100A1

Electrochemical assay of melanoma biomarker in human blood

Microfluidic Immunoassay System for Rapid Detection and Semi-Quantitative Determination of a Potential Serum Biomarker Mesothelin

Microfluidic SERS Biosensor based on Au-Semicoated Photonic Crystals for Melanoma Diagnosis

A microneedle patch for breast cancer screening via minimally invasive interstitial fluid sampling

An integrated micro-extracting system facilitates lesion-free biomacromolecules enrichment and detection

Fabrication of near infrared light responsive photoelectrochemical immunosensor for in vivo detection of melanoma cells

Expression of microphthalmia transcription factor, S100 protein, and HMB-45 in malignant melanoma and pigmented nevi

Simple, ultrasensitive detection of superoxide anion radical mutations in melanoma mice with SERS microneedles

Microfluidic-SERS sensing system based on dual signal amplification and aptamer for gastric cancer detection

A self-monitoring microneedle patch for light-controlled synergistic treatment of melanoma

In Situ Tyrosinase Monitoring by Wearable Microneedle Patch toward Clinical Melanoma Screening

A simple electrochemical immunosensor based on a chitosan/reduced graphene oxide nanocomposite for sensitive detection of biomarkers of malignant melanoma

Large Laser Spot-Swift Mapping Surface-Enhanced Raman Scattering on Ag Nanoparticle Substrates for Liquid Analysis in Serum-Based Cancer Diagnosis

Capture, Enrichment, and Mass Spectrometric Detection of Low-Molecular-Weight Biomarkers with Nanoporous Silicon Microparticles

Quantification of Cancer Biomarkers in Serum Using Scattering-Based Quantitative Single Particle Intensity Measurement with a Dark-Field Microscope

In Vivo Dynamic Monitoring of Circulating Melanoma Cells and the Inhibitory Effect of PD-L1 Inhibitor Based on PAFC Equipped with a Deep Learning Framework

Surface-enhanced Raman scatting microfluidic chip based on the identification competition strategy were used for rapid and simultaneous detection of liver cancer related proteins

On-chip dual detection of cancer biomarkers directly in serum based on self-assembled magnetic bead patterns and quantum dots

Molecular skin fluorescence imaging: A tool for evaluating early melanoma development

Label-Free Delineation of Human Uveal Melanoma Infiltration with Pump–Probe Microscopy